Cullinan Oncology LLC (CGEM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has a cash flow conversion efficiency ratio of -0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.88 Million) by net assets ($451.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cullinan Oncology LLC - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cullinan Oncology LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Cullinan Oncology LLC carry for a breakdown of total debt and financial obligations.
Cullinan Oncology LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cullinan Oncology LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Master Logistics Co Ltd
SHG:603967
|
0.060x |
|
Sella Real Estate
TA:SLARL
|
0.021x |
|
Thai Vegetable Oil Public Company Limited
BK:TVO-R
|
0.032x |
|
Ceepower Co Ltd
SHE:300062
|
0.033x |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
0.058x |
|
Tilray Inc
TO:TLRY
|
-0.014x |
|
Media and Games Invest PLC
F:M8G
|
0.001x |
|
Velocity Financial Llc
NYSE:VEL
|
0.018x |
Annual Cash Flow Conversion Efficiency for Cullinan Oncology LLC (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cullinan Oncology LLC from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Cullinan Oncology LLC market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $590.33 Million | $-145.30 Million | -0.246x | +16.80% |
| 2023-12-31 | $453.89 Million | $-134.28 Million | -0.296x | -24.96% |
| 2022-12-31 | $535.03 Million | $-126.66 Million | -0.237x | -131.86% |
| 2021-12-31 | $425.37 Million | $-43.43 Million | -0.102x | +31.30% |
| 2020-12-31 | $200.31 Million | $-29.77 Million | -0.149x | -128.38% |
| 2019-12-31 | $-39.91 Million | $-20.90 Million | 0.524x | -20.20% |
| 2018-12-31 | $-20.65 Million | $-13.55 Million | 0.656x | +64.77% |
| 2016-12-31 | $-574.85K | $-228.91K | 0.398x | +1962.80% |
| 2015-12-31 | $-1.24 Million | $-24.03K | 0.019x | -76.10% |
| 2014-12-31 | $-1.14 Million | $-91.72K | 0.081x | -88.70% |
| 2013-12-31 | $-1.00 Million | $-718.41K | 0.715x | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a … Read more